Introduction
============

Malaria is a leading human parasitic disease that increasingly threatens much of the world's population. The emergence of resistance by malarial parasites to currently commercially available antimalarial drugs is one of the major factors that lead to infection of more than 3 billion people living in high-incidence areas, particularly children and the elderly.[@b1-dddt-11-351],[@b2-dddt-11-351] Chloroquine resistance is most common in tropical and subtropical regions, particularly in Southeast Asia,[@b3-dddt-11-351],[@b4-dddt-11-351] and there has also been clinical and laboratory evidence of resistance to sulfadoxine, pyrimethamine, artemisinin, primaquine, mefloquine and quinine.[@b3-dddt-11-351],[@b5-dddt-11-351] *Plasmodium falciparum*, the most dominant causative agent of malaria, has high adaptability, brought about through many types of mutations, and has become resistant to nearly all antimalarial drugs.[@b3-dddt-11-351] Therefore, new families of bioactive compounds are needed in order to combat these problems and reduce the risk of resistance.

Malaysian tropical forests have not been fully scientifically explored even though they are among the oldest on the planet and as many as 1,300 plants are claimed to have medicinal properties.[@b6-dddt-11-351] Previous findings have shown that plants used by the Malaysian native population as alternative medicines are actually produced by endophytic microorganisms and may have the potential to treat malaria and many other parasitic diseases.[@b7-dddt-11-351],[@b8-dddt-11-351] Some of these antibiotic derivatives include alkaloid congeners as potential anticancer and antimicrobial agents;[@b9-dddt-11-351] nonadecene compounds as antifungals[@b10-dddt-11-351] and antioxidants;[@b11-dddt-11-351] as well as biologically active diketopiperazine (DKP) derivatives.[@b12-dddt-11-351],[@b13-dddt-11-351] DKP derivatives have demonstrated a variety of good biological activities, such as antibacterial, antiviral, antitumor, fungicidal and many more.[@b14-dddt-11-351],[@b15-dddt-11-351]

*Streptomyces*, a well-studied genus of gram-positive actinobacteria, shows outstanding chemical and morphological diversity with a distinct evolutionary line.[@b15-dddt-11-351] As these filamentous bacteria have a similar physiology as fungi,[@b16-dddt-11-351] most *Streptomyces* spp. have the ability to synthesize various secondary metabolites that have numerous medical applications, as antibiotic, herbicidal, antiparasitic, antitumor, antifungal and enzyme inhibiting agents.[@b17-dddt-11-351] Producing more than two-thirds of clinically useful antibiotics of natural origin,[@b18-dddt-11-351] endophytic *Streptomyces* spp. have the ability to inhibit a variety of human pathogens, including bacteria and fungi.[@b9-dddt-11-351],[@b19-dddt-11-351]--[@b22-dddt-11-351]

In this work, the DKP gancidin W (GW)[@b23-dddt-11-351] was isolated from the crude extract of an endophytic *Streptomyces* strain designated as SUK10, which was obtained from the bark of the *Shorea ovalis* tree. Screening of GW for antimalarial activity against *Plasmodium berghei* PZZ1/100 strain was carried out in order to assess the optimum in vivo antimalarial concentration of GW. Assessment of toxicity in terms of activity of enzymes in mice blood and total protein determination, as well as histopathology evaluation of the selected vital organs treated with GW, was also carried out.

Materials and methods
=====================

Production of crude extract
---------------------------

Nutrient broth (NB) (Sigma-Aldrich, Kuala Lumpur, Malaysia) was prepared at pH 7.0. To produce sufficient amount of isolates for extraction, five blocks of 5×5 mm International Streptomyces Project 2 agar enriched with *Streptomyces* SUK10 were cut and inoculated into 400 mL of autoclaved NB at pH 7.0 in a 1,000 mL conical flask. Fermentation was carried out using an orbital shaker at 28°C at rotation rate of 200 rpm for 21 days. By modifying a previous method,[@b22-dddt-11-351] the supernatant was then extracted three times using ethyl acetate to obtain 5.2 g of *Streptomyces* SUK10 crude extract.

Isolation and purification of bioactive compound
------------------------------------------------

Approximately 2.8 g of SUK10 crude extract was fractionated using flash chromatography (Reveleris^®^; Grace & Co, London, UK). The extract was chromatographed over 40 g of generic silica and eluted with hexane and ethyl acetate as the mobile phases A and B, respectively. The peaks were detected under UV light at absorption wavelengths of 245 and 310 nm coupled to an electron light scattering detector (ELSD). A gradient elution was done at 35 mL min^−1^, commencing with 100% hexane:100% ethyl acetate for 80.0 minutes, yielding 22 fractions (V1--V22), which were collected according to peak response. The purity of the fractions was further validated by normal phase thin-layer chromatography. Fractions 1--7 were monitored using 80:20 (v/v) of hexane/ethyl acetate as eluent, fractions 8--13 with 60:40 (v/v) hexane/ethyl acetate and fractions 14--22 with 98:2 (v/v) dichloromethane/methanol.

Identification of bioactive compound
------------------------------------

All fractions were subjected to nuclear magnetic resonance (NMR) spectroscopy in deuterated chloroform (CDCl~3~) for one-dimensional (1D) and 2D ^1^H-NMR analyses (400 MHz). Correlation spectroscopy (COSY) (12 scans), heteronuclear multiple-quantum coherence (HMQC) (24 scans) and heteronuclear multiple-bond coherence (HMBC) (32 scans) were also further implemented for the more purified fractions 11, 15 and 20. Fraction 15 was also subjected to ^13^C-NMR and distortionless enhancement by polarization transfer (DEPT) studies (both 4,000 scans). In addition to the NMR studies, liquid chromatography/high-resolution mass spectrometry (LC/HRMS) analysis (Accela autosampler; Grace & Co.) was also carried out, and the obtained spectral data were then compared with AntiBase database.

In vivo antimalarial screening of bioactive compound
----------------------------------------------------

ICR strain male mice (n=120, 25--30 g, 6--8 weeks old) were used in all animal experiments and were divided into 20 groups (n=6). All groups were housed in stainless steel cages under 12:12 hours with and without light conditions at 28°C with daily ad libitum feed. To initiate the infection, 0.1 mL of 1.0×10^6^ *P. berghei* PZZ1/100 parasitized red blood cell (RBC) solution was intraperitoneously administered into the host. To determine the best concentration, 50, 25, 12.5, 6.25 and 3.125 μg kg^−1^ bw of GW solutions were prepared by dissolving the obtained fractions of GW in 1.0 mL dimethyl sulfoxide (DMSO) as the stock compound solution before they were serially diluted with sterile distilled water to achieve the targeted concentrations. The 4-day suppression test[@b4-dddt-11-351] was chosen to implement the antimalarial screening, whereby day zero of the treatment was the day when the mice were treated with 0.1 mL of GW at all concentrations, immediately within 2 hours postinfection. In parallel, 0.1 mL of 10 mg kg^−1^ bw of dH~2~O-diluted quinine hydrochloride (QH) and 0.9% normal saline were respectively used as positive control (PC) and negative control (NC) solutions.

Similarly, successively, day one, day two and day three were referred when the same treatment was repeated for the next 3 days respectively without any infection. On day four, the parasitemia density (%) and inhibition rate (%) were calculated by a Giemsa blood smear from the treated and control mice using the following expressions: $$\begin{array}{l}
\text{Parasitemia~density} \\
{\mspace{14mu} = \frac{\text{Total~of~infected~red~blood~cells~observed}}{\text{Total~of~red~blood~cells~observed}} \times 100} \\
\end{array}$$and $$\begin{array}{l}
\text{Inhibition~rate} \\
{\mspace{14mu}\text{=}\frac{(\text{Parasitemia~density~of~NC}) - (\text{Parasitemia~density~of~~treated~mice})}{\text{Parasitemia~density~of~NC}} \times 100} \\
\end{array}$$

After 20 days postinfection, the mice were observed daily for their survival period (days). Treatment regime with inhibition rate of \>65% was considered as having antimalarial activity, and the mice group with the longest survival time was considered as receiving the best treatment.

In vivo toxicity assessment of the compound
-------------------------------------------

Mice with the same characteristics as during antimalarial screening (ICR strain, male, 25--30 g, 6--8 weeks old, n=36) were used for in vivo toxicity assessment. All animal experiments for toxicity assessment were conducted under the same Universiti Kebangsaan Malaysia Animal Ethics Committee (UKMAEC) approval code for antimalarial screening. The mice were divided into 12 groups (n=6), and all groups were subjected to the same conditions (28°C room temperature, stainless steel cage, 12:12 hours with and without light and daily ad libitum feed). At the best-detected concentration during antimalarial screening, toxicity tests were carried out on blood samples of mice treated with GW according to two types of toxicity regime: acute exposure (daily treatment for 7 days) and subacute exposure (daily treatment for 28 days). Each toxicity regime was divided into two groups of treatment: without infection and immediately within 2 hours after infection on day zero. For labeling purposes, all the mice groups were respectively labeled as TA for acute exposure without infection, TB (acute exposure immediately within 2 hours after infection), TC (subacute exposure without infection) and TD (subacute exposure immediately within 2 hours after infection). Data from the two control regimens, namely, normal mice without any infection and treatment (CN) and single-dose infected mice (CI), were also obtained for comparison. The animals were sacrificed under diethyl ether anesthesia, 0.8--1.0 mL of the blood was collected from each mouse by cardiac puncture on day eight and day 29 postexposure and tested for serum total protein (STP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) levels; their normal ranges (NRs) were compared with the data supplied by Research Animal Resources, University of Minnesota, MN, USA.

From the same diethyl ether-anesthetized mice used for biochemical toxicity tests, three vital organs, namely, liver, kidney and spleen, were individually collected for organ toxicity and histology studies. The infiltration procedure was done automatically by a tissue processor (Leica EG1169, Leica Biosystems \[SEA\] Pte. Ltd., Singapore). The tissues were next embedded in hot paraffin wax using an embedding machine (Shandon HistoCentre 2, GMI-Advance, Ramsey, MN, USA). These tissues were then cut (0.4--0.6 μm thick) by a microtome (Leica, RM2235). Histologic tissue preparation was done using hematoxylin-and-eosin (H--E) staining method. The H--E-stained slides for organ histology were observed using a computerized light microscopic camera (Zeiss Primo Star, New York Microscope Co., New York, NY, USA, and Dell, Dell Global Business Sdn. Bhd., Selangor, Malaysia) at 100× magnification by placing a drop of immersion oil on the surface of the slide or without the immersion oil at 40× magnification; this method was vital to give a clear picture of the internal structure of the targeted tissues, as well as for assessing and identifying abnormalities, toxicity and injuries in the tissues.

Ethics statement
----------------

The animal protocols used in this study were evaluated and approved by the UKMAEC of Universiti Kebangsaan Malaysia (UKM) under the given Animal Use Protocol code FSK/Biomed/341 and were in accordance with the UKM Laboratory Animal Care and Management Guidelines.

Statistical analysis
--------------------

All results were expressed as the mean ± standard deviation for every six mice per group (n=6). The Shapiro--Wilk test was used to determine all of the antimalarial screening and toxicity test parameters. Statistical significance was declared when the *P*-value was equal to or less than 0.05 (*P*≤0.05).

Results and discussion
======================

After culture optimization, the *Streptomyces* SUK10 isolate produced 10--12 mg of crude dried extract after 21 days of fermentation in NB at pH 7.0 and an agitation rate of 200 rpm. As shown in most previous studies,[@b8-dddt-11-351],[@b20-dddt-11-351],[@b24-dddt-11-351]--[@b28-dddt-11-351] biomass production was greater at higher agitation speeds. Higher rotating speeds during the fermentation process gave better aeration and oxygen could be efficiently supplied to the organisms for their growth and metabolism.[@b21-dddt-11-351],[@b25-dddt-11-351],[@b27-dddt-11-351] The fermentation process was scaled up to obtain a crude extract with a sufficient yield of 5.2 g. The crude extract was fractionated, and all 22 fractions were subjected to ^1^H-NMR experiments to determine purity and chemical structure. Based on the ^1^H-NMR analyses, fraction V15 was found to contain interesting signals that corresponded to the major constituent. V15 at 98% purity was isolated at 16.2 mg (0.31% yield) as a light brownish solid material with a molecular weight of 210.275 g/mol and molecular formula of C~11~H~18~N~2~O~2~, established by LC-high-resolution electrospray ionization mass spectrometry at a retention time of 7.17 minutes. Literature search revealed that the ^1^H- and ^13^C-NMR data for V15 ([Table 1](#t1-dddt-11-351){ref-type="table"}) were in accordance to the cyclodipeptide structure for *S*-prolyl-*R*-leucyl-diketopiperazine ([Figure 1](#f1-dddt-11-351){ref-type="fig"}), previously isolated from the sponges *Calyx cf. podatypa*[@b29-dddt-11-351] and *Callyspongia*.[@b30-dddt-11-351] A similar compound, named as gancidin W (GW) and elucidated as cyclo-(L-leu-L-pro) but with unknown absolute stereo-chemistry, was earlier isolated from strains of *Streptomyces gancidus*.[@b31-dddt-11-351],[@b32-dddt-11-351] In this study, the obtained natural product gave an optical rotation of \[α\]~D~ =−138.2° (*c*=1.0, EtOH), which was compatible with those isolated earlier from other *Streptomyces* strains.[@b31-dddt-11-351]--[@b34-dddt-11-351] Therefore, in this study, the nomenclature GW was assigned for the isolated compound V15.

With less than 2.0% of parasitemia density, there was a significant difference in this parameter (*P*\<0.05, n=6) between 3.125 μg kg^−1^ bw and the other four concentrations of GW. Nevertheless, in animals given a dose of 6.25 μg kg^−1^ bw, 1.43% of parasitemia density was observed, which was still far lower ([Table 2](#t2-dddt-11-351){ref-type="table"}) than that in animals given 3.125 μg kg^−1^ bw concentration. [Figure 2](#f2-dddt-11-351){ref-type="fig"} shows the microscopic blood smear from mice treated with 0.1 mL of GW at five different concentrations. At 0.1 mL of 10 mg kg^−1^ bw of QH administered to the PC group, no infected RBCs were found in any of the mice on day four postinfection regardless of the tested concentrations. Previous studies[@b4-dddt-11-351],[@b33-dddt-11-351],[@b35-dddt-11-351],[@b36-dddt-11-351] demonstrated that no physical side effects were observed in the host treated with 10% DMSO. Therefore, it is hypothesized that there is no crucial requirement to have 10% DMSO as one of our control treatments.

*P. berghei* PZZ1/100 strain, which is the most established and reliable rodent malaria parasite, was used as the infectious agent in this study. This strain was a quinine-sensitive and chloroquine-resistant strain,[@b37-dddt-11-351]--[@b39-dddt-11-351] making QH application as a control drug in this study valid and significant. Moreover, *P. berghei* is a rodent malaria parasite that was used to test the antimalarial property of the bioactive compound before this compound can be introduced in clinical trials.[@b40-dddt-11-351] Stepniewska et al[@b37-dddt-11-351] documented that in terms of molecular structure, there was a similarity between the monomeric structure of lactate dehydrogenase from all strains of *P. berghei* (PbLDH) and *P. falciparum* lactate dehydrogenase (PfLDH). These two forms of the enzyme are important in glycolysis because of the generation of ATP as an energy source, and they are persistent in the erythrocytes of the host.[@b41-dddt-11-351]--[@b43-dddt-11-351] This fact proves that the mouse model is valid to test in vivo antimalarial activity using *P. berghei* as it was also comparable with results from infection with *P. falciparum* in a human study.

A group of scientists discussed the relative merits of a range of animal models and their overlap with the complex clinical syndromes of human malaria.[@b44-dddt-11-351],[@b45-dddt-11-351] These researchers agreed that malaria research using male rodents was acceptable and understandable and that rodents were 95% systemic pathologically, endocrinologically and immunologically reflective of experimental human *P. falciparum* malaria. This was based on the results from a study showing favorable exploitation by the female hormonal system when an infectious agent was administered.[@b43-dddt-11-351] The interferences from any female hormones in microbiological and pathological studies should be considered a bias because the results obtained by research would be difficult to analyze. Among the research efforts was a study on the new antibiotic azithromycin, which has been shown to be effective in male mice and monkeys and has undergone a successful trial to prevent malaria in humans.[@b43-dddt-11-351]

GW was subjected to antimalarial screening across a narrow range of five different concentrations in order to determine which dose gave the best antimalarial activity. The value for parasitemia density directly reflected the value of percentage inhibition, where the higher the percentage inhibition -- the more effective the treatment was.[@b4-dddt-11-351] The inhibition rate at 3.125 μg kg^−1^ bw dose was found to exhibit the greatest value. Reaching almost 80% inhibition rate, there was a significant difference (*P*\<0.05, n=6) between the 3.125 μg kg^−1^ bw group and the groups given the other four concentrations. Inhibition rate higher than 65%, which was considered a benchmark for in vivo antimalarial activity, was also reached at 6.25 μg kg^−1^ bw dose, whereby this value was far better than the other three dose concentrations ([Table 3](#t3-dddt-11-351){ref-type="table"}).

The survival time of mice treated with 3.125 μg kg^−1^ bw dose of GW was steadily almost twofold longer than that of mice given 12.5 μg kg^−1^ bw and was proportionately higher than that for mice given a dose of 6.25 μg kg^−1^ bw ([Figure 3](#f3-dddt-11-351){ref-type="fig"}). As previously demonstrated, both in vivo and in vitro analyses[@b4-dddt-11-351],[@b14-dddt-11-351],[@b46-dddt-11-351]--[@b48-dddt-11-351] predicted that the survival times of the treated mice would be longer at a higher parasite inhibition rate. The longest period of mouse survival (235.53±2.20 days) was achieved by treatment with GW at a dose concentration of 3.125 μg kg^−1^ bw, which was significantly higher than that with other dose concentrations (*P*\<0.05, n=6). In conjunction with this, surprisingly, the remaining 50% (n=3) of the group treated with GW at this concentration individually managed to survive until 291.13±0.5 days postinfection. Based on previous documentations,[@b49-dddt-11-351]--[@b53-dddt-11-351] this period of survival time was considered to almost reach the life span of normal male mice at approximately 12--18 months. Until 411 postinfection days, all PC mice survived and this observation was in parallel with results of previous in vivo antimalarial studies,[@b4-dddt-11-351],[@b14-dddt-11-351],[@b47-dddt-11-351],[@b48-dddt-11-351],[@b52-dddt-11-351] while the NC mice survived to 7--9 days postinfection, as also recorded in this study.

There was no comparable benchmark found in the literature for the animals' survival period in in vivo studies when test groups partially had their respective control groups.[@b53-dddt-11-351] Therefore, it was not surprising that the survival time at 12.5 μg kg^−1^ bw was longer than that at 25 μg kg^−1^ bw, although the inhibition rate at 25 μg kg^−1^ bw was slightly higher. As recommended by the World Health Organization (WHO), for every single dose of an antimalarial drug, regardless of the type of drug and malaria etiological agent, the daily therapeutic dosage in treating malaria was 5--25 mg kg^−1^ bw for the first month of medication.[@b54-dddt-11-351],[@b55-dddt-11-351] This dosage was significantly higher than the best concentration recorded in this study.

Except for the mice in the TD regime (those immediately subjected to subacute exposure within 2 hours after the 28-day postinfection period), ALT and AST levels slightly increased. At the treatment dose of 3.125 μg kg^−1^ bw, all tested enzymes and total protein levels were in their NRs, regardless of the type of exposure regime ([Table 4](#t4-dddt-11-351){ref-type="table"}). The biochemical toxicity test results in this study revealed that all of the enzymes and STPs levels for all the regime groups were within the NR. However, there was a slightly higher average recorded for ALT and AST levels in the mice group that was treated daily with 3.125 μg kg^−1^ bw of GW for 28 days. However, it is too early to conclude that the higher levels of ALT and AST in this study for this group was due to damaged liver or oversecretion of these enzymes into the blood stream. The Department of Research Animal Resources, University of Minnesota (MN, USA), circulated the guidelines that the values of ALT, AST, ALP and STP can vary and be beyond the NR depending on the age, bw, gender and the animal model.[@b56-dddt-11-351] In the mice group receiving a daily dose of 3.125 μg kg^−1^ bw of GW for 4 weeks, the values of ALT and AST exceeded the maximum normal values at 3 and 5 IU L^−1^, respectively. These values were already considered significant because blood was sampled after 28 days post-treatment, at which time point, the mice were 4 weeks older from day 0 of their treatment regime. Most enzymes will be oversecreted as the animals mature in age.[@b45-dddt-11-351] Therefore, the normal levels of these enzymes were basically set up according to the animal's age together with other factors mentioned herein. Another factor to consider in this study was the animals' experimental environment.[@b57-dddt-11-351],[@b58-dddt-11-351] Animals (n=6) of the same gender were housed together in a transparent walled box (45×25×25 cm). The animals were situated in a stress condition, which induced oversecretion and elevation of ALT and AST levels from their NRs. In addition, the mice in this group received the treatment daily by the intraperitoneal route for 28 days. In an earlier study,[@b57-dddt-11-351] under similar stress conditions, the AST and ALT levels significantly reached a twofold increase from the NR.

The selected tissues from all mice in the groups were stained with H--E. None of the tissues showed any abnormality, including the organs taken from the mice in the TD regime group (treated daily with 3.125 μg kg^−1^ bw of GW for 28 days); prior to this, their recorded ALT and AST levels were slightly higher than normal. [Figures 4](#f4-dddt-11-351){ref-type="fig"}[](#f5-dddt-11-351){ref-type="fig"}--[6](#f6-dddt-11-351){ref-type="fig"} show the microscopic H--E histology slides for the toxicity assessment of the kidney, spleen and liver tissues, respectively, on selected mice treated with 3.125 μg kg^−1^ bw of GW from each of the regime groups. Histologically, there was no morphological difference between the control and the treatment groups, regardless of whether they were administered acute or subacute regimens. At the same time, no physical injury or swelling, morphological abnormalities or color changes of the targeted organs were spotted during the isolation process from the sacrificed mice.

In this study, the histopathology assessment was observed for three vital organs of the mice treated with 3.125 μg kg^−1^ bw of GW. Neither in the acute (7 days) nor in the subacute (28 days) treatment regime, or in the control treatment groups, were activated kupffer cells, cytoplasmic vacuolation and sinusoidal dilatation observed by H--E staining of liver, which could basically indicate their association with the presence of abnormal morphology or toxicity characteristics.[@b59-dddt-11-351] There was no evidence of hepatic injuries in any of the treatment groups as they exhibited defined histological structures in their liver tissue without any signs of cytoplasmic condensation, mild vascular inflammatory changes, congested nuclear changes and necrosis.[@b60-dddt-11-351] Similarly, no presence of granular and cellular cast was noticed in the kidney tissue of all treated and control mice groups regardless of their regime. There was also a normal histological structure of the kidney glomerulus and tubules, with no glomerular atrophy and tubular necrosis, as well as no vascular shrinkage being observed in the renal tubules at the cortical zone, which could directly indicate a degenerative phenomenon.[@b61-dddt-11-351],[@b62-dddt-11-351]

The histopathology assessment in the sectional spleen tissue in all treatment regimens did not reveal any evidence of vascular changes and periarterial hyperplasia of the red pulp and white pulp or malpighian follicle nodules. Positively, there was also no proliferation of the mononuclear cells around the sinusoid cord structure, which generally could have activated the accumulation of organic compounds in the blood stream.[@b63-dddt-11-351],[@b64-dddt-11-351] No shrinkage or deformed size and shape of splenic cord that could indicate any spleen degenerative phenomenon was evidenced.[@b52-dddt-11-351] Onkar and Govardhan[@b65-dddt-11-351] and Rungruang et al[@b66-dddt-11-351] claimed that in the same sacrificed mice, any abnormalities spotted and visualized on the four vital organs, namely, liver, spleen, lungs and kidney, were also histologically recorded by the H--E staining method. In this study, concurrently, the selected organs of the mice were extracted for histopathology assessment after their blood samples were taken for biochemical tests. Because there were no ultimate evidences of blood toxicity in all the mice groups, in parallel, similar observations were also expected from the histopathology evidences of these selected organ tissues of all mice groups. These findings showed that GW at 3.125 μg kg^−1^ bw left no undesired effects on the treated host.

Conclusion
==========

Administration of antimalarial drugs totally depends on the regime combination, stage of infection, the side effects experienced by the infected host and the type of plasmodial species.[@b47-dddt-11-351],[@b52-dddt-11-351],[@b67-dddt-11-351],[@b68-dddt-11-351] Quinine has been proven to kill all *Plasmodium* cells, regardless of the species. However, it is only effective in the early stages of malarial infection, during which generally, the host will experience asymptomatic signs.[@b69-dddt-11-351],[@b70-dddt-11-351] All the untreated control mice in this study died between 7 and 9 days postinfection, as described in previous in vivo antimalarial studies,[@b4-dddt-11-351],[@b18-dddt-11-351],[@b51-dddt-11-351],[@b60-dddt-11-351],[@b71-dddt-11-351] regardless of the type of animal model used.

Although GW has been previously reported from other *Streptomyces* species,[@b31-dddt-11-351],[@b32-dddt-11-351],[@b34-dddt-11-351] its antimalarial properties have not yet been revealed. In fact, our results indicate that GW is one of the metabolites responsible for the in vivo antimalarial activity of the ethyl acetate crude extract from SUK10. The outcomes of the presented study indicate that *Streptomyces* SUK10 living endophytically in *S. ovalis* tree is a good source of a potential antimalarial agent with relatively very low toxicity. Apart from the fact that the progression of the erythrocytic cycle in the *Plasmodium*-infected host is still poorly understood,[@b36-dddt-11-351] there is also a tendency to obtain more significant values for certain antimalarial parameters in particular cycles or stages of the *Plasmodium* life cycle,[@b43-dddt-11-351],[@b44-dddt-11-351],[@b46-dddt-11-351],[@b54-dddt-11-351] which have not been considered in this study.
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![Structure of gancidin W.](dddt-11-351Fig1){#f1-dddt-11-351}

![Microscopic thin blood smear of mice treated with GW.\
**Notes:** Mice were treated with 0.1 mL of GW at 50 (**A**), 25 (**B**), 12.5 (**C**), 6.25 (**D**) and 3.125 μg kg^−1^ bw (**E**). The arrows indicate the RBCs infected with *Plasmodium berghei* at all stages of the parasite's life cycle at the time of mice sacrifice: immature trophozoite (ring stage), trophozoite, schizont and gametocyte. Microscopic images were viewed at 100× magnification.\
**Abbreviations:** bw, body weight; GW, gancidin W; RBC, red blood cells.](dddt-11-351Fig2){#f2-dddt-11-351}

![Survival period (days) of the mice treated with GW as compared to the NC group mice at five different concentrations, observed after 20 days postinfection.\
**Notes:** Data presented as mean ± standard deviation. Error bars represent standard error.\
**Abbreviations:** bw, body weight; GW, gancidin W; NC, negative control.](dddt-11-351Fig3){#f3-dddt-11-351}

![The microscopic hematoxylin-and-eosin histology slides of kidney for toxicity assessment of selected mice.\
**Notes:** Mice were treated with 3.125 μg kg^−1^ bw of GW in TA (**A**), TB (**B**), TC (**C**), TD (**D**), CN (**E**) and CI (**F**) groups. TA stands for acute exposure without infection, TB stands for acute exposure immediately within 2 hours after infection, TC represents subacute exposure without infection and TD stands for subacute exposure immediately within 2 hours after infection; CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice. No signs of toxic effects in the kidney were observed for all groups of mice treated with 3.125 μg kg^−1^ bw of GW. The kidney showed normal cellular structure with intact glomeruli and tubules. There was also no sign of necrosis or cellular damage. Microscopic images were viewed at 100× magnification.\
**Abbreviations:** bw, body weight; GW, gancidin W.](dddt-11-351Fig4){#f4-dddt-11-351}

![The microscopic hematoxylin-and-eosin histology slides of spleen for toxicity assessment of selected mice.\
**Notes:** Mice were treated with 3.125 μg kg^−1^ bw of GW in TA (**A**), TB (**B**), TC (**C**), TD (**D**), CN (**E**) and CI (**F**) groups. TA stands for acute exposure without infection, TB stands for acute exposure immediately within 2 hours after infection, TC represents subacute exposure without infection and TD stands for subacute exposure immediately within 2 hours after infection; CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice. No sign of toxic effects in the spleen were observed for all groups of mice treated with 3.125 μg kg^−1^ bw of GW. Organization of white pulp and red pulp marginal zone was normal. No hypodense splenic lesions, splenomas (a type of benign and typically asymptomatic lesion), or tuberous sclerosis were observed for all groups of mice. Microscopic images were viewed at 100× magnification.\
**Abbreviations:** bw, body weight; GW, gancidin W.](dddt-11-351Fig5){#f5-dddt-11-351}

![The microscopic hematoxylin-and-eosin histology slides of liver for toxicity assessment of selected mice.\
**Notes:** Mice were treated with 3.125 μg kg^−1^ bw of GW in TA (**A**), TB (**B**), TC (**C**), TD (**D**), CN (**E**) and CI (**F**) groups. TA stands for acute exposure without infection, TB stands for acute exposure immediately within 2 hours after infection, TC represents subacute exposure without infection and TD stands for subacute exposure immediately within 2 hours after infection; CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice. No sign of toxic effects in the liver were observed for all groups of mice treated with 3.125 μg kg^−1^ bw of GW. This included structural degeneration of hepatocytes, presence of Kupfer cells, as well as increased number of mitotic figures. The hepatocytes seemed intact while the sinusoids were not congested. Microscopic images were viewed at 100× magnification.\
**Abbreviations:** bw, body weight; GW, gancidin W.](dddt-11-351Fig6){#f6-dddt-11-351}

###### 

Assignment of the ^1^H- and ^13^C-NMR signals of GW at 400 MHz in CDCl~3~

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Position   Atom/molecule element   Cyclo-(*S*-Pro-*R*-Leu)[@b32-dddt-11-351]\    SUK10-V15 (GW)\                                                                   
                                     \[α\]~D~ =−91°                                \[α\]~D~ =−138.2° (*c*=1.0, EtOH)                                                 
  ---------- ----------------------- --------------------------------------------- ----------------------------------- --------------------------------------------- -------
  1          C                       NA                                            171.4                               NA                                            170.0

  2          NA                      NA                                            NA                                  NA                                            NA

  3          CH~2~                   3.6--3.5 (*m*)                                45.6                                3.6--3.5 (*m*)                                45.8

  4          CH~2~                   1.94--1.86 (*m*), 2.02--1.99 (*m*)            22.8                                1.94--1.85 (*m*), 2.03--1.96 (*m*)            23.1

  5          CH~2~                   2.13 (*m*), 2.33 (*m*)                        28.2                                2.11 (*m*), 2.33 (*m*)                        29.2

  6          CH                      4.12 (*t*, *J* =8.1)                          59.1                                4.11 (*t*, *J* =7.8)                          59.3

  7          C                       NA                                            167.1                               NA                                            166.0

  8          N--H                    5.91 (*brs*)                                  NA                                  6.03 (*brs*)                                  NA

  9          CH                      4.01 (*dd*, *J* =9.4, 3.4)                    53.4                                4.01 (*dd*, *J* =9.2, 3.6)                    53.7

  10         CH~2~                   2.01 (*m*), 1.52 (*ddd, J* =14.5, 9.6, 4.9)   38.7                                2.02 (*m*), 1.52 (*ddd, J* =14.5, 9.6, 5.0)   39.0

  11         CH                      1.76--1.69 (*m*)                              24.8                                1.79--1.69 (*m*)                              25.0

  12         Me                      0.94 (*d*, *J* =6.5)                          22.8                                0.94 (*d*, *J* =6.5)                          23.0

  13         Me                      1.00 (*d*, *J* =6.5)                          21.1                                0.98 (*d*, *J* =6.5)                          22.0
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** δ~H~ represents the coupling constants (*J*) for H and δ~C~ the coupling constants (*J*) for C.

**Abbreviations:** CDCl~3~, deuterated chloroform; EtOH, ethanol; GW, gancidin W; Hz, hertz; NMR, nuclear magnetic resonance; SUK10, endophytic actinobacterial *Streptomyces* strain; *s*, singlet; *d*, doublet; *t*, triplet; *m*, multiplet; *q*, quadruplet; *br*, broad; NA, not applicable.

###### 

Parasitemia density (%) of the mice treated with gancidin W (GW) compared with positive control (PC) and negative control (NC) groups on day four at five different concentrations

  Group   Parasitemia density (%)                                                                                                                                                                                                                                                
  ------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  PC      0                                                      0                                                      0                                                      0                                                                                                 0
  NC      6.82±2.7[\*](#tfn4-dddt-11-351){ref-type="table-fn"}   7.19±1.8[\*](#tfn4-dddt-11-351){ref-type="table-fn"}   6.53±3.2[\*](#tfn4-dddt-11-351){ref-type="table-fn"}   5.91±0.                                                                                           7.02±2.2[\*](#tfn4-dddt-11-351){ref-type="table-fn"}
  GW      3.41±1.9[\*](#tfn4-dddt-11-351){ref-type="table-fn"}   2.45±1.3[\*](#tfn4-dddt-11-351){ref-type="table-fn"}   2.55±3.3[\*](#tfn4-dddt-11-351){ref-type="table-fn"}   1.43±1.[\*](#tfn4-dddt-11-351){ref-type="table-fn"},[a](#tfn5-dddt-11-351){ref-type="table-fn"}   1.51±2.2[\*](#tfn4-dddt-11-351){ref-type="table-fn"},[a](#tfn5-dddt-11-351){ref-type="table-fn"}

**Notes:**

Concentration of GW in micrograms per kilogram body weight;

value in mean ± standard deviation;

significantly different from the other GW concentration groups (*P*\<0.05, n=6, two-way analysis of variance).

###### 

Inhibition percentage (%) of the mice treated with gancidin W (GW) compared with positive control (PC) and negative control (NC) groups on day four at five different concentrations

  Group   Inhibition percentage (%)                                                                                                                                                                                                                                                   
  ------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  PC      100                                                     100                                                     100                                                     100                                                                                                 100
  NC      0                                                       0                                                       0                                                       0                                                                                                   0
  GW      50.09±0.1[\*](#tfn7-dddt-11-351){ref-type="table-fn"}   65.95±0.3[\*](#tfn7-dddt-11-351){ref-type="table-fn"}   60.97±0.5[\*](#tfn7-dddt-11-351){ref-type="table-fn"}   75.87±0.8[\*](#tfn7-dddt-11-351){ref-type="table-fn"},[a](#tfn8-dddt-11-351){ref-type="table-fn"}   78.46±0.2[\*](#tfn7-dddt-11-351){ref-type="table-fn"},[a](#tfn8-dddt-11-351){ref-type="table-fn"},[b](#tfn9-dddt-11-351){ref-type="table-fn"}

**Notes:**

Concentration of GW in micrograms per kilogram body weight;

value in mean ± standard deviation;

significantly different from the other GW concentration groups (inhibition \>65%) at these concentrations;

concentration 3.125 μg kg^−1^ bw is considered to show the best value for antimalarial activity.

**Abbreviation:** bw, body weight.

###### 

ALT, AST and ALP levels (IU L^−1^), as well as the STP level (g dL^−1^), in the mice treated with gancidin W (GW) at 3.125 μg kg^−1^ bw under four toxicity regimens

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Regime                                            ALT\                                                                                                   AST\                                                                                                    ALP\                                                      STP\
                                                    (IU L^−1^)                                                                                             (IU L^−1^)                                                                                              (IU L^−1^)                                                (g dL^−1^)
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------
  Acute exposure                                                                                                                                                                                                                                                                                                             

   TA                                               41.81±2.14[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                133.13±2.04[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                62.76±2.33[\*](#tfn11-dddt-11-351){ref-type="table-fn"}   6.12±2.32[\*](#tfn11-dddt-11-351){ref-type="table-fn"}

   TB                                               45.20±1.13[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                125.93±2.12[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                59.42±2.97[\*](#tfn11-dddt-11-351){ref-type="table-fn"}   7.21±3.81[\*](#tfn11-dddt-11-351){ref-type="table-fn"}

  Subacute exposure                                                                                                                                                                                                                                                                                                          

   TC                                               67.57±2.91[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                167.76±2.27[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                69.29±2.90[\*](#tfn11-dddt-11-351){ref-type="table-fn"}   7.93±2.01[\*](#tfn11-dddt-11-351){ref-type="table-fn"}

   TD                                               95.03±2.02[\*](#tfn11-dddt-11-351){ref-type="table-fn"},[a](#tfn12-dddt-11-351){ref-type="table-fn"}   212.01±2.33[\*](#tfn11-dddt-11-351){ref-type="table-fn"},[b](#tfn13-dddt-11-351){ref-type="table-fn"}   68.03±2.10[\*](#tfn11-dddt-11-351){ref-type="table-fn"}   8.83±3.90[\*](#tfn11-dddt-11-351){ref-type="table-fn"}

  Control exposure                                                                                                                                                                                                                                                                                                           

   CN                                               41.03±3.91[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                111.62±1.19[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                61.46±2.46[\*](#tfn11-dddt-11-351){ref-type="table-fn"}   6.40±1.01[\*](#tfn11-dddt-11-351){ref-type="table-fn"}

   CI                                               44.83±1.11[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                134.43±4.01[\*](#tfn11-dddt-11-351){ref-type="table-fn"}                                                58.32±2.97[\*](#tfn11-dddt-11-351){ref-type="table-fn"}   6.80±3.06[\*](#tfn11-dddt-11-351){ref-type="table-fn"}

  Indicator                                                                                                                                                                                                                                                                                                                  

   NR[‡](#tfn14-dddt-11-351){ref-type="table-fn"}   40--93                                                                                                 92--206                                                                                                 54--115                                                   5.8--9.5
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Value in mean ± standard deviation.

ALT level recorded for the mice in the TD group, which was slightly higher than the NR.

AST level recorded for the mice in the TD group, which was slightly higher than the NR.

NR indicates the normal range data for ICR strain male mice aged \>8 weeks old for the indicator, as supplied by Research Animal Resources, University of Minnesota, MN, USA; the data present the values under the four toxicity regimens -- TA, TB, TC and TD -- as compared with the control regimens CN and CI. TA, stands for acute exposure to gancidin W without infection; TB, acute exposure immediately within 2 hours after infection; TC, subacute exposure without infection; TD, subacute exposure immediately within 2 hours after infection. CN, normal control mice without any infection and treatment; CI, single-dose infected normal mice.

**Abbreviations:** ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; bw, body weight; NR, normal range; STP, serum total protein.
